AR108074A1 - Composiciones de hormona esteroide en aceites de cadena media - Google Patents

Composiciones de hormona esteroide en aceites de cadena media

Info

Publication number
AR108074A1
AR108074A1 ARP170100831A ARP170100831A AR108074A1 AR 108074 A1 AR108074 A1 AR 108074A1 AR P170100831 A ARP170100831 A AR P170100831A AR P170100831 A ARP170100831 A AR P170100831A AR 108074 A1 AR108074 A1 AR 108074A1
Authority
AR
Argentina
Prior art keywords
medium chain
estradiol
progesterone
pharmaceutical composition
chain oil
Prior art date
Application number
ARP170100831A
Other languages
English (en)
Inventor
Jason D Legassie
Frederick D Sancilio
Thorsteinn Thorsteinsson
Philip B Inskeep
Peter H R Persicaner
Annette Shadiack
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of AR108074A1 publication Critical patent/AR108074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica capaz de formar micelas tras la exposición al entorno gástrico. La composición farmacéutica es apta para administrar hormonas esteroides, y la combinación de estradiol y en particular progesterona, a un sujeto que tiene la necesidad de ellas. Reivindicación 1: Una composición farmacéutica para proporcionar biodisponibilidad oral mejorada de estradiol y/o progesterona, la composición farmacéutica comprende: estradiol, progesterona, un polisorbato, y un aceite de cadena media, donde el aceite de cadena media comprende al menos aproximadamente 50 por ciento en peso de un monoglicérido predominantemente de cadena media; y el estradiol y la progesterona ambas se solubilizan por completo. Reivindicación 8: La composición farmacéutica de la reivindicación 1, que comprende además un aceite de ricino hidrogenado de polioxietileno. Reivindicación 9: La composición farmacéutica de la reivindicación 1, que comprende además un derivado de d-a-tocoferol polietilenglicol succinato. Reivindicación 21: Una composición farmacéutica de estradiol y progesterona oral, completamente solubilizada, que comprende: estradiol, progesterona y un polisorbato en una relación de peso de desde aproximadamente 1:2 a aproximadamente 2:1; y un aceite de cadena media que comprende una mezcla de mono- y diglicéridos de cadena media, el aceite de cadena media no contiene más de aproximadamente 10 por ciento en peso de triglicéridos. Reivindicación 33: Una composición farmacéutica para proporcionar biodisponibilidad oral mejorada de estradiol y/o progesterona, la composición farmacéutica comprende: estradiol, progesterona, un polisorbato, y un aceite de cadena media, donde el aceite de cadena media comprende al menos aproximadamente 50 por ciento en peso de un primer componente de aceite de cadena media; y el estradiol y la progesterona ambas se solubilizan por completo.
ARP170100831A 2016-04-01 2017-04-03 Composiciones de hormona esteroide en aceites de cadena media AR108074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317402P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
AR108074A1 true AR108074A1 (es) 2018-07-11

Family

ID=59960645

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100831A AR108074A1 (es) 2016-04-01 2017-04-03 Composiciones de hormona esteroide en aceites de cadena media

Country Status (3)

Country Link
US (1) US20170281647A1 (es)
AR (1) AR108074A1 (es)
WO (1) WO2017173191A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) * 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림

Also Published As

Publication number Publication date
US20170281647A1 (en) 2017-10-05
WO2017173191A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
AR108074A1 (es) Composiciones de hormona esteroide en aceites de cadena media
AR108072A1 (es) Composiciones de hormona esteroide en aceites de cadena media
Sengupta et al. Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
AR108073A1 (es) Composición farmacéutica de hormona esteroide, método
ECSP17057848A (es) Composiciones farmacéuticas para terapia combinada
AR108075A1 (es) Composición farmacéutica de hormona esteroide
Patel et al. Self microemulsifying drug delivery system of lurasidone hydrochloride for enhanced oral bioavailability by lymphatic targeting: in vitro, Caco-2 cell line and in vivo evaluation
PH12015500158A1 (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
CA2929865C (en) Sprayable topical carrier and composition comprising phosphatidylcholine
CY1124104T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
RU2007142204A (ru) Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
AR100562A1 (es) Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
HRP20140097T1 (hr) Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu
BR112016029338A2 (pt) creme transdérmico
JP2015504924A5 (es)
NZ631833A (en) Emulsion formulations
CO2019002555A2 (es) Composición farmacéutica
RU2013100984A (ru) Офтальмологические композиции для введения активных жирорастворимых ингредиентов
JP2015516418A5 (es)
RU2016150868A (ru) Пероральная фармацевтическая композиция изотретиноина
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
AR084235A1 (es) Composiciones farmaceuticas que comprenden alisporivir
Rosso et al. Supersaturable self-microemulsifying delivery systems: An approach to enhance oral bioavailability of benzimidazole anticancer drugs

Legal Events

Date Code Title Description
FB Suspension of granting procedure